About this document

XTANDI® (Enzalutamide) Prescribing Info by aniketmahale130 is a document available to read on EtoBox.

XTANDI (enzalutamide) is an androgen receptor inhibitor approved for treating castration-resistant and metastatic castration-sensitive prostate cancer. Key warnings include risks of seizures, posterior reversible encephalopathy syndrome, hypersensitivity, ischemic heart disease, and falls/fractures, with specific recommendations for discontinuation in severe cases. The recommended dosage is 160 mg taken orally once daily, and it should be used in conjunction with a gonadotropin-releasing hormone analog or f

Author

aniketmahale130

Language

EN